Get the Stockscreener App
1.88
1.62%
0.03
After Hours:
1.88
X T L Biopharmaceuticals Ltd Adr stock is traded at $1.88, with a volume of 3,525.
It is up +1.62% in the last 24 hours and up +8.05% over the past month.
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
See More
Previous Close:
$1.85
Open:
$1.82
24h Volume:
3,525
Relative Volume:
0.09
Market Cap:
$10.24M
Revenue:
-
Net Income/Loss:
$-2.25M
P/E Ratio:
-3.9496
EPS:
-0.476
Net Cash Flow:
-
1W Performance:
+0.00%
1M Performance:
+8.05%
6M Performance:
-28.38%
1Y Performance:
+66.37%
1-Day Range:
$1.7757
$1.888
1-Week Range:
$1.70
$1.90
52-Week Range:
$0.76
$4.9897
X T L Biopharmaceuticals Ltd Adr Stock (XTLB) Company Profile
Name
X T L Biopharmaceuticals Ltd Adr
Sector
Industry
Phone
-
Address
-
Compare XTLB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XTLB
X T L Biopharmaceuticals Ltd Adr
|
1.88 | 10.24M | 0 | -2.25M | 0 | -0.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
X T L Biopharmaceuticals Ltd Adr Stock (XTLB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-08-15 | Initiated | H.C. Wainwright | Buy |
X T L Biopharmaceuticals Ltd Adr Stock (XTLB) Latest News
XTL Biopharmaceuticals Adjusts Shares, Eyes Expansion - TipRanks
XTL Biopharmaceuticals Resolves Dispute with Social Proxy - TipRanks
U.S. shares higher at close of trade; Dow Jones Industrial Average up 1.03% - MSN
XTL Biopharmaceuticals Faces Financial Dispute After Acquisition - TipRanks
XTL Biopharmaceuticals Expands with AI Company Acquisition - TipRanks
XTL Biopharmaceuticals Confirms Board and Auditor Appointments - Investing.com
XTL Biopharmaceuticals Announces Shareholder Meeting Outcomes - TipRanks
A stock that deserves closer examination: X.T.L. Biopharmaceuticals Ltd. ADR (XTLB) – US Post News - US Post News
XTL Biopharmaceuticals Announces Upcoming Shareholder MeetingTipRanks.com - TipRanks
XTL Biopharmaceuticals acquires AI firm Social Proxy By Investing.com - Investing.com
XTL Biopharmaceuticals acquires AI firm Social Proxy - Investing.com India
XTL Biopharmaceuticals Acquires SOCIAL PROXY LTD.TipRanks.com - TipRanks
XTL Entered Definitive Agreement to Acquire The Social Proxy - GlobeNewswire Inc.
XTL Biopharmaceuticals Regains Nasdaq ComplianceTipRanks.com - TipRanks
XTL Biopharmaceuticals Convenes Extraordinary General MeetingTipRanks.com - TipRanks
Enhance Your Investment Strategy with Altman Z-Score Screener By Investing.com - Investing.com India
XTL Biopharmaceuticals Acquires The Social Proxy - TipRanks
The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Vote, Mesoblast Sinks On Data - Benzinga
The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Sarepta Flags Potential Delay In Gene Therapy Trial - Benzinga
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection - Yahoo Finance
List of US Companies Releasing Earnings (EPS) Today - FX Leaders
The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 T - Benzinga
The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rock - Benzinga
The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon - Yahoo Finance
Benzinga's Daily Biotech Pulse: Karyopharm's STORM Study, Inogen Rallies On Earnings - Yahoo Finance
15 Biggest Mid-Day Gainers For ThursdayCuris (NASDAQ:CRIS), Federal Agricultural (NYSE:AGM), Canadian - Benzinga
Mid-Afternoon Market Update: Monotype Drops On Earnings Miss; LMI Aerospace Shares Spike HigherDeere ( - Benzinga
Mid-Morning Market Update: Markets Open Lower; Tesla Motors Delivers 17,400 Vehicles in Fourth Quarter - Benzinga
Morning Market LosersCentury Aluminum (NASDAQ:CENX) - Benzinga
X T L Biopharmaceuticals Ltd Adr Stock (XTLB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):